Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05090371 · ClinicalTrials.gov registry record · Phase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

A Phase 4 study of Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 4
Development phase
136
Enrollment target
20
Study locations

NCT05090371 is a Phase 4 study of Relapsing Remitting Multiple Sclerosis that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 136 participants, below the 197-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05090371, a Phase 4 study of Relapsing Remitting Multiple Sclerosis, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
136 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.

Conditions Studied

Relapsing Remitting Multiple Sclerosis

Interventions

  • DRUG Ofatumumab
  • DRUG Disease modifying treatment (DMT)

Study Locations (20)

Florida

  • Neurology of Central FL Res Ctr - Altamonte Springs
  • S And D Clinical Research - Cape Coral
  • Homestead Assoc In Research Inc - Homestead
  • Neurology Associates PA - Maitland
  • Orlando Health Clinical Trials - Orlando
  • Emerald Coast Neurology - Pensacola
  • University Of South Florida - Tampa

Alabama

  • Alabama Neurology Associates PC - Birmingham
  • North Central Neurology Associates PC - Cullman

Arizona

  • Radiant Research Chandler - Chandler
  • Arizona Neuroscience Research LLC - Phoenix

Michigan

  • Henry Ford Hospital - Detroit
  • Memorial Healthcare - Owosso

California

  • University of California at Los Angeles - Torrance

Idaho

  • Kootenai Health - Coeur d'Alene

Louisiana

  • Neuro Medial Clinic of Central Louisiana - Alexandria

Maryland

  • International Neurorehab Institute - Lutherville

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2022-03-02
Est. Completion 2027-03-01
Phase Phase 4

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05090371

The ClinicalTrials.gov registry entry for NCT05090371 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (31% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ofatumumab is the first listed.

NCT05090371 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT05090371 about?

NCT05090371 is a clinical study titled "A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation". This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanc...

What is the current status of trial NCT05090371?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2022-03-02. Estimated completion is 2027-03-01.

What conditions does trial NCT05090371 study?

This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.

What interventions are being tested in trial NCT05090371?

The interventions under investigation include: Ofatumumab (DRUG), Disease modifying treatment (DMT) (DRUG).

Who is sponsoring clinical trial NCT05090371?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05090371 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Remitting Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Remitting Multiple Sclerosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.